Antidepressant/anxiolytic drug in which PAC1 receptor antagonist is used
This invention relates to an antidepressant/anxiolytic drug comprising a compound represented by the following formula (I) or (II), wherein R 1 is a hydrogen atom, a C 1-6 -alkyl group, a C 1-6 -alkoxy group, a C 2-6 -alkenyloxy group, a halogen atom, a C 1-6 -haloalkyl group, a C 1-6 -haloalkoxy group, or a substituted or unsubstituted phenyl group; R 2 is a hydrogen atom, a C 1-6 -alkyl group, a C 1-6 -alkoxy group, a C 2-6 -alkenyloxy group, a halogen atom, a C 1-6 -haloalkyl group, a C 1-6 -haloalkoxy group, or a substituted or unsubstituted phenyl group; and R is an indazolyl group substituted with a halogen atom; a substituted or unsubstituted phenyl group; a pyrazolyl group; or a substituted or unsubstituted aralkyl group; or a salt thereof, or a solvate thereof.
1 . A method for treating and/or preventing a disease that is anxiety disorder, stress disorder, and/or depression, comprising administering to a subject in need thereof an effective amount of a compound of formula (I):
wherein
R 1 is a hydrogen atom, a C 1-6 -alkyl group, a C 1-6 -alkoxy group, a C 2-6 -alkenyloxy group, a halogen atom, a C 1-6 -haloalkyl group, a C 1-6 -haloalkoxy group, or a substituted or unsubstituted phenyl group; and
R 2 is a hydrogen atom, a C 1-6 -alkyl group, a C 1-6 -alkoxy group, a C 2-6 -alkenyloxy group, a halogen atom, a C 1-6 -haloalkyl group, a C 1-6 -haloalkoxy group, or a substituted or unsubstituted phenyl group;
or a salt thereof, or a solvate thereof.
2 . The method according to claim 1 , wherein the compound of formula (I) or the salt thereof, or the solvate thereof is orally administered.
3 . A method for treating and/or preventing a disease that is anxiety disorder, stress disorder, and/or depression, comprising administering to a subject in need thereof an effective amount of a compound of formula (II):
wherein R is an indazolyl group substituted with a halogen atom; a substituted or unsubstituted phenyl group; a pyrazolyl group; or a substituted or unsubstituted aralkyl group;
or a salt thereof, or a solvate thereof.
4 . The method according to claim 3 , wherein R is an indazolyl group substituted with a halogen atom.
5 . The method according to claim 3 , wherein the halogen is chlorine.
6 . The method according to claim 3 , wherein the compound of formula (II) or the salt thereof, or the solvate thereof is orally administered.
7 . The method according to claim 4 , wherein the compound of formula (II) or the salt thereof, or the solvate thereof is orally administered.
8 . The method according to claim 5 , wherein the compound of formula (II) or the salt thereof, or the solvate thereof is orally administered.
9 . The method according to claim 1 , wherein the disease is depression.
10 . The method according to claim 1 , wherein the disease is an anxiety disorder.
11 . The method according to claim 1 , wherein the disease is a stress disorder.
12 . The method according to claim 3 , wherein the disease is depression.
13 . The method according to claim 3 , wherein the disease is an anxiety disorder.
14 . The method according to claim 3 , wherein the disease is a stress disorder.